{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:20:25Z","timestamp":1772119225057,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Graduate School of Medicine, Keio University","award":["scholarship"],"award-info":[{"award-number":["scholarship"]}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23H03068"],"award-info":[{"award-number":["23H03068"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04208-8","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:33:10Z","timestamp":1762144390000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The antitumor mechanism of immuno-flap treatment in a rat model of head and neck cancer"],"prefix":"10.1007","volume":"74","author":[{"given":"Hiroaki","family":"Mori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuto","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chie","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akari","family":"Kanematsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Ashizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazue","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruo","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Iizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoatsu","family":"Ikeya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshichika","family":"Yasunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Araki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"4208_CR1","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","volume":"24","author":"RN Amaria","year":"2018","unstructured":"Amaria RN, Reddy SM, Tawbi HA et al (2018) Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 24:1649\u20131654","journal-title":"Nat Med"},{"key":"4208_CR2","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.jtcvs.2023.09.073","volume":"167","author":"H Feldman","year":"2024","unstructured":"Feldman H, Sepesi B, Leung CH et al (2024) Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg 167:1444\u20131453","journal-title":"J Thorac Cardiovasc Surg"},{"key":"4208_CR3","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1158\/1078-0432.CCR-22-0413","volume":"28","author":"M Zhu","year":"2022","unstructured":"Zhu M, Chen C, Foster NR et al (2022) Pembrolizumab in combination with neoadjuvant chemoradiotherapy for patients with resectable adenocarcinoma of the gastroesophageal junction. Clin Cancer Res 28:3021\u20133031","journal-title":"Clin Cancer Res"},{"key":"4208_CR4","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1200\/JCO.2005.05.2308","volume":"24","author":"F Kamangar","year":"2006","unstructured":"Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137\u20132150","journal-title":"J Clin Oncol"},{"key":"4208_CR5","doi-asserted-by":"publisher","first-page":"489","DOI":"10.4065\/83.4.489","volume":"83","author":"S Marur","year":"2008","unstructured":"Marur S, Forastiere AA (2008) Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc 83:489\u2013501","journal-title":"Mayo Clin Proc"},{"key":"4208_CR6","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1158\/1078-0432.CCR-22-0666","volume":"28","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Wu B, Peng G et al (2022) Neoadjuvant chemoimmunotherapy for the treatment of locally advanced head and neck squamous cell carcinoma: a single-arm phase 2 clinical trial. Clin Cancer Res 28:3268\u20133276","journal-title":"Clin Cancer Res"},{"key":"4208_CR7","first-page":"203","volume":"66","author":"EE Cohen","year":"2016","unstructured":"Cohen EE, LaMonte SJ, Erb NL et al (2016) American Cancer Society head and neck cancer survivorship care guideline. CA Cancer J Clin 66:203\u2013239","journal-title":"CA Cancer J Clin"},{"key":"4208_CR8","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1002\/wjo2.22","volume":"8","author":"M Mark","year":"2022","unstructured":"Mark M, Eggerstedt M, Urban MJ, Al-Khudari S, Smith R, Revenaugh P (2022) Designing an evidence-based free-flap pathway in head and neck reconstruction. World J Otorhinolaryngol Head Neck Surg 8:126\u2013132","journal-title":"World J Otorhinolaryngol Head Neck Surg"},{"key":"4208_CR9","doi-asserted-by":"publisher","first-page":"444","DOI":"10.21037\/gs.2020.03.16","volume":"10","author":"PL Myers","year":"2021","unstructured":"Myers PL, Nelson JA, Allen RJ Jr (2021) Alternative flaps in autologous breast reconstruction. Gland Surg 10:444\u2013459","journal-title":"Gland Surg"},{"key":"4208_CR10","doi-asserted-by":"publisher","first-page":"eabj9905","DOI":"10.1126\/scitranslmed.abj9905","volume":"16","author":"AM Miller","year":"2024","unstructured":"Miller AM, Ko\u015falo\u011flu-Yal\u00e7\u0131n Z, Westernberg L et al (2024) A functional identification platform reveals frequent, spontaneous neoantigen-specific T cell responses in patients with cancer. Sci Transl Med 16:eabj9905","journal-title":"Sci Transl Med"},{"key":"4208_CR11","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber JS, Carlino MS, Khattak A et al (2024) Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403:632\u2013644","journal-title":"Lancet"},{"key":"4208_CR12","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.ccell.2022.08.002","volume":"40","author":"CSK Leung","year":"2022","unstructured":"Leung CSK, Van den Eynde BJ (2022) Combining personalized neoantigen vaccination with chemotherapy and anti-PD-1 to treat NSCLC. Cancer Cell 40:903\u2013905","journal-title":"Cancer Cell"},{"key":"4208_CR13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","volume":"183","author":"PA Ott","year":"2020","unstructured":"Ott PA, Hu-Lieskovan S, Chmielowski B et al (2020) A phase Ib trial of personalized neoantigen therapy plus Anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell 183:347\u2013362","journal-title":"Cell"},{"key":"4208_CR14","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas LA, Sethna Z, Soares KC et al (2023) Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618:144\u2013150","journal-title":"Nature"},{"key":"4208_CR15","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/cas.12586","volume":"106","author":"K Inoue","year":"2015","unstructured":"Inoue K, Saegusa N, Omiya M et al (2015) Immunologically augmented skin flap as a novel dendritic cell vaccine against head and neck cancer in a rat model. Cancer Sci 106:143\u2013150","journal-title":"Cancer Sci"},{"key":"4208_CR16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.21873\/anticanres.15500","volume":"42","author":"H Miyata","year":"2022","unstructured":"Miyata H, Akiyama Y, Iizuka A et al (2022) Development of an automatic measurement method for CD8 and PD-1 positive T cells using image analysis software. Anticancer Res 42:419\u2013427","journal-title":"Anticancer Res"},{"key":"4208_CR17","doi-asserted-by":"publisher","first-page":"4417","DOI":"10.21873\/anticanres.15942","volume":"42","author":"K Yasui","year":"2022","unstructured":"Yasui K, Kondou R, Miyata H et al (2022) Immunological and genetic characterization of patients with head and neck cancer who developed recurrence. Anticancer Res 42:4417\u20134428","journal-title":"Anticancer Res"},{"key":"4208_CR18","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/0022-1759(94)00253-S","volume":"178","author":"M Chen-Woan","year":"1995","unstructured":"Chen-Woan M, Delaney CP, Fournier V et al (1995) A new protocol for the propagation of dendritic cells from rat bone marrow using recombinant GM-CSF, and their quantification using the mAb OX-62. J Immunol Methods 178:157\u2013171","journal-title":"J Immunol Methods"},{"key":"4208_CR19","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/jlb.59.2.196","volume":"59","author":"M Chen-Woan","year":"1996","unstructured":"Chen-Woan M, Delaney CP, Fournier V et al (1996) In vitro characterization of rat bone marrow-derived dendritic cells and their precursors. J Leukoc Biol 59:196\u2013207","journal-title":"J Leukoc Biol"},{"key":"4208_CR20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1756-0500-2-12","volume":"2","author":"G Tiurbe","year":"2009","unstructured":"Tiurbe G, Matuschek A, K\u00e4mmerer U et al (2009) Inhibitory effects of rat bone marrow-derived dendritic cells on na\u00efve and alloantigen-specific CD4+ T cells: a comparison between dendritic cells generated with GM-CSF plus IL-4 and dendritic cells generated with GM-CSF plus IL-10. BMC Res Notes 2:12","journal-title":"BMC Res Notes"},{"key":"4208_CR21","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1189\/jlb.1AB0914-433RR","volume":"99","author":"M N'diaye","year":"2016","unstructured":"N\u2019diaye M, Warnecke A, Flytzani S et al (2016) Rat bone marrow-derived dendritic cells generated with GM-CSF\/IL-4 or FLT3L exhibit distinct phenotypical and functional characteristics. J Leukoc Biol 99:437\u2013446","journal-title":"J Leukoc Biol"},{"key":"4208_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1148\/radiol.2020200443","volume":"297","author":"HJ Park","year":"2020","unstructured":"Park HJ, Kim KW, Pyo J et al (2020) Incidence of pseudoprogression during immune checkpoint inhibitor therapy for solid tumors: a systematic review and meta-analysis. Radiology 297:87\u201396","journal-title":"Radiology"},{"key":"4208_CR23","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.2217\/fon-2019-0183","volume":"15","author":"JJ Failing","year":"2019","unstructured":"Failing JJ, Dudek OA, Marin Acevedo JA et al (2019) Biomarkers of hyperprogression and pseudoprogression with immune checkpoint inhibitor therapy. Future Oncol 15:2645\u20132656","journal-title":"Future Oncol"},{"key":"4208_CR24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.intimp.2018.03.018","volume":"58","author":"Q Wang","year":"2018","unstructured":"Wang Q, Gao J, Wu X (2018) Pseudoprogression and hyperprogression after checkpoint blockade. Int Immunopharmacol 58:125\u2013135","journal-title":"Int Immunopharmacol"},{"key":"4208_CR25","doi-asserted-by":"publisher","first-page":"6473","DOI":"10.21873\/anticanres.14669","volume":"40","author":"K Mitsuya","year":"2020","unstructured":"Mitsuya K, Akiyama Y, Iizuka A et al (2020) Alpha-type-1 polarized dendritic cell-based vaccination in newly diagnosed high-grade glioma: a phase II clinical trial. Anticancer Res 40:6473\u20136484","journal-title":"Anticancer Res"},{"key":"4208_CR26","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.immuni.2018.09.024","volume":"49","author":"CS Garris","year":"2018","unstructured":"Garris CS, Arlauckas SP, Kohler RH et al (2018) Successful Anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-\u03b3 and IL-12. Immunity 49:1148\u20131161","journal-title":"Immunity"},{"key":"4208_CR27","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1158\/1078-0432.CCR-19-2217","volume":"26","author":"AP Algazi","year":"2020","unstructured":"Algazi AP, Twitty CG, Tsai KK et al (2020) Phase II trial of IL-12 plasmid transfection and PD-1 blockade in immunologically quiescent melanoma. Clin Cancer Res 26:2827\u20132837","journal-title":"Clin Cancer Res"},{"key":"4208_CR28","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1158\/2326-6066.CIR-19-0359","volume":"8","author":"SK Greaney","year":"2020","unstructured":"Greaney SK, Algazi AP, Tsai KK et al (2020) Intratumoral plasmid IL12 electroporation therapy in patients with advanced melanoma induces systemic and intratumoral T-cell responses. Cancer Immunol Res 8:246\u2013254","journal-title":"Cancer Immunol Res"},{"key":"4208_CR29","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1038\/sj.gt.3301353","volume":"7","author":"Y Akiyama","year":"2000","unstructured":"Akiyama Y, Watanabe M, Maruyama K, Ruscetti FW, Wiltrout RH, Yamaguchi K (2000) Enhancement of antitumor immunity against B16 melanoma tumor using genetically modified dendritic cells to produce cytokines. Gene Ther 7:2113\u20132121","journal-title":"Gene Ther"},{"key":"4208_CR30","doi-asserted-by":"publisher","first-page":"6287","DOI":"10.4049\/jimmunol.1004036","volume":"186","author":"K Fujimoto","year":"2011","unstructured":"Fujimoto K, Karuppuchamy T, Takemura N et al (2011) A new subset of CD103+CD8alpha+ dendritic cells in the small intestine expresses TLR3, TLR7, and TLR9 and induces Th1 response and CTL activity. J Immunol 186:6287\u20136295","journal-title":"J Immunol"},{"key":"4208_CR31","doi-asserted-by":"publisher","first-page":"13031","DOI":"10.1073\/pnas.192162899","volume":"99","author":"J Lehmann","year":"2002","unstructured":"Lehmann J, Huehn J, de la Rosa M et al (2002) Expression of the integrin alpha Ebeta 7 identifies unique subsets of CD25+ as well as CD25- regulatory T cells. Proc Natl Acad Sci U S A 99:13031\u201313036","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4208_CR32","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1158\/2326-6066.CIR-17-0341","volume":"5","author":"D Mittal","year":"2017","unstructured":"Mittal D, Vijayan D, Putz EM et al (2017) Interleukin-12 from CD103+ Batf3-dependent dendritic cells required for NK-cell suppression of metastasis. Cancer Immunol Res 5:1098\u20131108","journal-title":"Cancer Immunol Res"},{"key":"4208_CR33","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.ccell.2014.10.008","volume":"26","author":"L Zitvogel","year":"2014","unstructured":"Zitvogel L, Kroemer G (2014) CD103+ dendritic cells producing interleukin-12 in anticancer immunosurveillance. Cancer Cell 26:591\u2013593","journal-title":"Cancer Cell"},{"key":"4208_CR34","doi-asserted-by":"publisher","first-page":"6171","DOI":"10.1038\/s41467-020-19833-3","volume":"11","author":"NF Kuhn","year":"2020","unstructured":"Kuhn NF, Lopez AV, Li X, Cai W, Daniyan AF, Brentjens RJ (2020) CD103+ cDC1 and endogenous CD8+ T cells are necessary for improved CD40L-overexpressing CAR T cell antitumor function. Nat Commun 11:6171","journal-title":"Nat Commun"},{"key":"4208_CR35","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1084\/jem.20051100","volume":"202","author":"B Johansson-Lindbom","year":"2005","unstructured":"Johansson-Lindbom B, Svensson M, Pabst O et al (2005) Functional specialization of gut CD103+ dendritic cells in the regulation of tissue-selective T cell homing. J Exp Med 202:1063\u20131073","journal-title":"J Exp Med"},{"key":"4208_CR36","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/s41590-024-01802-3","volume":"25","author":"MHBA Hamid","year":"2024","unstructured":"Hamid MHBA, Cespedes PF, Jin C et al (2024) Unconventional human CD61 pairing with CD103 promotes TCR signaling and antigen-specific T cell cytotoxicity. Nat Immunol 25:834\u2013846","journal-title":"Nat Immunol"},{"key":"4208_CR37","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1002\/hed.27787","volume":"46","author":"R Sato","year":"2024","unstructured":"Sato R, Komatsuda H, Inoue T et al (2024) Combined approach for predicting the efficacy of nivolumab in head and neck carcinoma by tissue and soluble expression of PD-L1 and PD-L2. Head Neck 46:2233\u20132243","journal-title":"Head Neck"},{"key":"4208_CR38","doi-asserted-by":"publisher","first-page":"4298","DOI":"10.1038\/s41467-022-31941-w","volume":"13","author":"R Saddawi-Konefka","year":"2022","unstructured":"Saddawi-Konefka R, O\u2019Farrell A, Faraji F et al (2022) Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC. Nat Commun 13:4298","journal-title":"Nat Commun"},{"key":"4208_CR39","doi-asserted-by":"publisher","first-page":"106795","DOI":"10.1016\/j.oraloncology.2024.106795","volume":"152","author":"M Kono","year":"2024","unstructured":"Kono M, Saito S, Rokugo M et al (2024) Enhanced oral versus flank lymph node T cell response parallels anti-PD-1 efficacy in head and neck cancer. Oral Oncol 152:106795","journal-title":"Oral Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04208-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04208-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04208-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:45:17Z","timestamp":1764600317000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04208-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":39,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4208"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04208-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7305506\/v1","asserted-by":"object"}]},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"6 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethical approval to conduct this study was obtained through the Institutional Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This study was an animal experiment using rats.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This study was an animal experiment using rats.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"355"}}